Evidence map›Paper›PMID 23220998›Full record

ArticleClinical and vaccine immunology : CVI2013

The live attenuated Actinobacillus pleuropneumoniae triple-deletion mutant ΔapxIC ΔapxIIC ΔapxIV-ORF1 strain, SLW05, Immunizes pigs against lethal challenge with Haemophilus parasuis.

Shulin Fu, Jiwen Ou, Minmin Zhang, Juan Xu, Huazhen Liu, Jinlin Liu, Fangyan Yuan, Huanchun Chen, Weicheng Bei

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review of advanced research on swineFrontiers in immunology · 2025
    Review
  4. Article
  5. Article
  6. Construction and immunization with double mutant ΔJournal of veterinary science · 2020
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Shulin FuState Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, China.
Jiwen Ou
Minmin Zhang
Juan Xu
Huazhen Liu
Jinlin Liu
Fangyan Yuan
Huanchun Chen
Weicheng Bei
Huazhong Agricultural University · CNCentral China Normal University · CNChinese Academy of Agricultural Sciences · CNHubei Academy of Agricultural Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haemophilus parasuis and Actinobacillus pleuropneumoniae both belong to the family Pasteurellaceae and are major respiratory pathogens that cause large economic losses in the pig industry worldwide. We previously constructed an attenuated A. pleuropneumoniae serovar 1 live vaccine prototype, SLW05 (ΔapxIC ΔapxIIC ΔapxIV-ORF1), which is able to produce nontoxic but immunogenic ApxIA, ApxIIA, and ApxIVA. This triple-deletion mutant strain was shown to elicit protective immunity against virulent A. pleuropneumoniae. In the present study, we investigated whether immunization with SLW05 could also protect against lethal challenge with virulent H. parasuis SH0165 (serovar 5) or MD0322 (serovar 4). The SLW05 strain was found to elicit a strong humoral antibody response in pigs and to confer significant protection against challenge with a lethal dose of H. parasuis SH0165 or MD0322. IgG subtype analysis revealed that SLW05 induces a bias toward a Th1-type immune response and stimulates interleukin 2 (IL-2) and gamma interferon (IFN-γ) production. Moreover, antisera from SLW05-vaccinated pigs efficiently inhibited both A. pleuropneumoniae and H. parasuis growth in a whole-blood assay. This is the first report that a live attenuated A. pleuropneumoniae vaccine with SLW05 can protect against lethal H. parasuis infection, which provides a novel approach for developing an attenuated H. parasuis vaccine.

Indexed as

Actinobacillus InfectionsActinobacillus pleuropneumoniaeAnimalsAntibodies, BacterialBacterial ProteinsBacterial VaccinesHaemophilus InfectionsHaemophilus parasuisHemolysin ProteinsInterferon-gammaInterleukin-2Sequence DeletionSwineSwine DiseasesVaccines, AttenuatedAntibodies, BacterialApxII toxin, bacteriaApxI toxin, BacteriaApxIVA protein, Actinobacillus pleuropneumoniaeBacterial ProteinsBacterial VaccinesHemolysin ProteinsInterferon-gammaInterleukin-2Vaccines, Attenuated

Identifiers

PMID23220998
PMCPMC3571286
OpenAlexW2166342722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.